title: [Osteoporosis treatment by anti-RANKL antibody].
abstract: Anti-RANKL antibody, that is called Denosumab, is a fully human monoclonal antibody to the receptor activator of nuclear factor-κB ligand (RANKL) which blocks its binding to RANK, inhibiting the differentiation, activation and survival of osteoclact. Denosumab given subcutaneously twice yearly for 3 years was associated with a reduction in the risk of vertebral, non-vertebral and hip fractures but not with serious adverse events in postmenopausal women with osteoporosis. Evidence is available about its effect in patients with varying degrees of fracture risk. New horizon would be brought about by Denosumab in Japan, new molecular targeting pharmaceutics in the treatment of osteoporosis.
authors.affiliation: Internal Medicine 1, Shimane University Faculty of Medicine, Japan.
authors.forename: Toshitsugu
authors.initials: T
authors.lastname: Sugimoto
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D002986:Clinical Trials as Topic; D000069448:Denosumab; D050723:Fractures, Bone / Q000517:prevention & control; D006801:Humans; D058990:Molecular Targeted Therapy; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy* / Q000235:genetics; D053245:RANK Ligand / Q000008:administration & dosage / Q000276:immunology*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D053245:RANK Ligand; D000069448:Denosumab